Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology

Orietta Spinelli, Alessandro Rambaldi, Francesca Rigo, Pamela Zanghì, Elena D'Agostini, Giulia Amicarelli, Francesco Colotta, Mariadomenica Divona, Claudia Ciardi, Francesco Lo Coco, Giulia Minnucci

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The diagnostic work-up of acute promyelocytic leukemia (APL) includes the cytogenetic demonstration of the t(15;17) translocation and/or the PML-RARA chimeric transcript by RQ-PCR or RT-PCR. This latter assays provide suitable results in 3-6 hours. We describe here two new, rapid and specific assays that detect PML-RARA transcripts, based on the RT-QLAMP (Reverse Transcription-Quenching Loop-mediated Isothermal Amplification) technology in which RNA retrotranscription and cDNA amplification are carried out in a single tube with one enzyme at one temperature, in fluorescence and real time format. A single tube triplex assay detects bcr1 and bcr3 PML-RARA transcripts along with GUS housekeeping gene. A single tube duplex assay detects bcr2 and GUSB. In 73 APL cases, these assays detected in 16 minutes bcr1, bcr2 and bcr3 transcripts. All 81 non-APL samples were negative by RT-QLAMP for chimeric transcripts whereas GUSB was detectable. In 11 APL patients in which RTPCR yielded equivocal breakpoint type results, RT-QLAMP assays unequivocally and accurately defined the breakpoint type (as confirmed by sequencing). Furthermore, RT-QLAMP could amplify two bcr2 transcripts with particularly extended PML exon 6 deletions not amplified by RQ-PCR. RT-QLAMP reproducible sensitivity is 10-3 for bcr1 and bcr3 and 10-2 for bcr2 thus making this assay particularly attractive at diagnosis and leaving RQ-PCR for the molecular monitoring of minimal residual disease during the follow up. In conclusion, PML-RARA RT-QLAMP compared to RT-PCR or RQ-PCR is a valid improvement to perform rapid, simple and accurate molecular diagnosis of APL.

Original languageEnglish
Pages (from-to)50-58
Number of pages9
JournalOncoscience
Volume2
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Acute Promyelocytic Leukemia
Reverse Transcription
Technology
Polymerase Chain Reaction
Essential Genes
Residual Neoplasm
Cytogenetics
Exons
Leukemia
Complementary DNA
Fluorescence
RNA
Temperature
Enzymes

Keywords

  • APL
  • LAMP
  • Molecular diagnosis
  • PML-RARA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Spinelli, O., Rambaldi, A., Rigo, F., Zanghì, P., D'Agostini, E., Amicarelli, G., ... Minnucci, G. (2015). Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. Oncoscience, 2(1), 50-58. https://doi.org/10.18632/oncoscience.114

Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. / Spinelli, Orietta; Rambaldi, Alessandro; Rigo, Francesca; Zanghì, Pamela; D'Agostini, Elena; Amicarelli, Giulia; Colotta, Francesco; Divona, Mariadomenica; Ciardi, Claudia; Lo Coco, Francesco; Minnucci, Giulia.

In: Oncoscience, Vol. 2, No. 1, 2015, p. 50-58.

Research output: Contribution to journalArticle

Spinelli, O, Rambaldi, A, Rigo, F, Zanghì, P, D'Agostini, E, Amicarelli, G, Colotta, F, Divona, M, Ciardi, C, Lo Coco, F & Minnucci, G 2015, 'Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology', Oncoscience, vol. 2, no. 1, pp. 50-58. https://doi.org/10.18632/oncoscience.114
Spinelli, Orietta ; Rambaldi, Alessandro ; Rigo, Francesca ; Zanghì, Pamela ; D'Agostini, Elena ; Amicarelli, Giulia ; Colotta, Francesco ; Divona, Mariadomenica ; Ciardi, Claudia ; Lo Coco, Francesco ; Minnucci, Giulia. / Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. In: Oncoscience. 2015 ; Vol. 2, No. 1. pp. 50-58.
@article{b91bf20e953c400eb339ad59acaaf9f5,
title = "Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology",
abstract = "The diagnostic work-up of acute promyelocytic leukemia (APL) includes the cytogenetic demonstration of the t(15;17) translocation and/or the PML-RARA chimeric transcript by RQ-PCR or RT-PCR. This latter assays provide suitable results in 3-6 hours. We describe here two new, rapid and specific assays that detect PML-RARA transcripts, based on the RT-QLAMP (Reverse Transcription-Quenching Loop-mediated Isothermal Amplification) technology in which RNA retrotranscription and cDNA amplification are carried out in a single tube with one enzyme at one temperature, in fluorescence and real time format. A single tube triplex assay detects bcr1 and bcr3 PML-RARA transcripts along with GUS housekeeping gene. A single tube duplex assay detects bcr2 and GUSB. In 73 APL cases, these assays detected in 16 minutes bcr1, bcr2 and bcr3 transcripts. All 81 non-APL samples were negative by RT-QLAMP for chimeric transcripts whereas GUSB was detectable. In 11 APL patients in which RTPCR yielded equivocal breakpoint type results, RT-QLAMP assays unequivocally and accurately defined the breakpoint type (as confirmed by sequencing). Furthermore, RT-QLAMP could amplify two bcr2 transcripts with particularly extended PML exon 6 deletions not amplified by RQ-PCR. RT-QLAMP reproducible sensitivity is 10-3 for bcr1 and bcr3 and 10-2 for bcr2 thus making this assay particularly attractive at diagnosis and leaving RQ-PCR for the molecular monitoring of minimal residual disease during the follow up. In conclusion, PML-RARA RT-QLAMP compared to RT-PCR or RQ-PCR is a valid improvement to perform rapid, simple and accurate molecular diagnosis of APL.",
keywords = "APL, LAMP, Molecular diagnosis, PML-RARA",
author = "Orietta Spinelli and Alessandro Rambaldi and Francesca Rigo and Pamela Zangh{\`i} and Elena D'Agostini and Giulia Amicarelli and Francesco Colotta and Mariadomenica Divona and Claudia Ciardi and {Lo Coco}, Francesco and Giulia Minnucci",
year = "2015",
doi = "10.18632/oncoscience.114",
language = "English",
volume = "2",
pages = "50--58",
journal = "Oncoscience",
issn = "2331-4737",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology

AU - Spinelli, Orietta

AU - Rambaldi, Alessandro

AU - Rigo, Francesca

AU - Zanghì, Pamela

AU - D'Agostini, Elena

AU - Amicarelli, Giulia

AU - Colotta, Francesco

AU - Divona, Mariadomenica

AU - Ciardi, Claudia

AU - Lo Coco, Francesco

AU - Minnucci, Giulia

PY - 2015

Y1 - 2015

N2 - The diagnostic work-up of acute promyelocytic leukemia (APL) includes the cytogenetic demonstration of the t(15;17) translocation and/or the PML-RARA chimeric transcript by RQ-PCR or RT-PCR. This latter assays provide suitable results in 3-6 hours. We describe here two new, rapid and specific assays that detect PML-RARA transcripts, based on the RT-QLAMP (Reverse Transcription-Quenching Loop-mediated Isothermal Amplification) technology in which RNA retrotranscription and cDNA amplification are carried out in a single tube with one enzyme at one temperature, in fluorescence and real time format. A single tube triplex assay detects bcr1 and bcr3 PML-RARA transcripts along with GUS housekeeping gene. A single tube duplex assay detects bcr2 and GUSB. In 73 APL cases, these assays detected in 16 minutes bcr1, bcr2 and bcr3 transcripts. All 81 non-APL samples were negative by RT-QLAMP for chimeric transcripts whereas GUSB was detectable. In 11 APL patients in which RTPCR yielded equivocal breakpoint type results, RT-QLAMP assays unequivocally and accurately defined the breakpoint type (as confirmed by sequencing). Furthermore, RT-QLAMP could amplify two bcr2 transcripts with particularly extended PML exon 6 deletions not amplified by RQ-PCR. RT-QLAMP reproducible sensitivity is 10-3 for bcr1 and bcr3 and 10-2 for bcr2 thus making this assay particularly attractive at diagnosis and leaving RQ-PCR for the molecular monitoring of minimal residual disease during the follow up. In conclusion, PML-RARA RT-QLAMP compared to RT-PCR or RQ-PCR is a valid improvement to perform rapid, simple and accurate molecular diagnosis of APL.

AB - The diagnostic work-up of acute promyelocytic leukemia (APL) includes the cytogenetic demonstration of the t(15;17) translocation and/or the PML-RARA chimeric transcript by RQ-PCR or RT-PCR. This latter assays provide suitable results in 3-6 hours. We describe here two new, rapid and specific assays that detect PML-RARA transcripts, based on the RT-QLAMP (Reverse Transcription-Quenching Loop-mediated Isothermal Amplification) technology in which RNA retrotranscription and cDNA amplification are carried out in a single tube with one enzyme at one temperature, in fluorescence and real time format. A single tube triplex assay detects bcr1 and bcr3 PML-RARA transcripts along with GUS housekeeping gene. A single tube duplex assay detects bcr2 and GUSB. In 73 APL cases, these assays detected in 16 minutes bcr1, bcr2 and bcr3 transcripts. All 81 non-APL samples were negative by RT-QLAMP for chimeric transcripts whereas GUSB was detectable. In 11 APL patients in which RTPCR yielded equivocal breakpoint type results, RT-QLAMP assays unequivocally and accurately defined the breakpoint type (as confirmed by sequencing). Furthermore, RT-QLAMP could amplify two bcr2 transcripts with particularly extended PML exon 6 deletions not amplified by RQ-PCR. RT-QLAMP reproducible sensitivity is 10-3 for bcr1 and bcr3 and 10-2 for bcr2 thus making this assay particularly attractive at diagnosis and leaving RQ-PCR for the molecular monitoring of minimal residual disease during the follow up. In conclusion, PML-RARA RT-QLAMP compared to RT-PCR or RQ-PCR is a valid improvement to perform rapid, simple and accurate molecular diagnosis of APL.

KW - APL

KW - LAMP

KW - Molecular diagnosis

KW - PML-RARA

UR - http://www.scopus.com/inward/record.url?scp=84934897099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934897099&partnerID=8YFLogxK

U2 - 10.18632/oncoscience.114

DO - 10.18632/oncoscience.114

M3 - Article

VL - 2

SP - 50

EP - 58

JO - Oncoscience

JF - Oncoscience

SN - 2331-4737

IS - 1

ER -